BioLife Solutions, Inc.

09/03/2026

👀 ICYMI…

We’re co-hosting an intriguing new recombinant protein webinar with Cell & Gene Therapy Review on Wednesday, September 23 at 11am ET/8am PT/5pm CEST.

💭 You may be thinking, “I’m already getting 'ok' or 'good enough' performance and recovery results in my cell culture workflow. Why should I consider other options?”

Dave Briner, our Senior Product Manager of Cell Culture, and Liz Stewart, PhD, Senior Product Manager of Qkine, will share some eye opening factors to consider with cytokine and growth factor choice.

Common issues:

❌ Inconsistencies from batch-to-batch
❌ Reproducibility difficulties when scaling-up
❌ Cost fluctuations
❌ Lower than desired or expected bioactivity, performance, and recovery
❌ Lack of GMP and regulatory-ready documentation

Dave and Liz will also expand on how closed-system containers and processes may streamline scale-up and reduce reliance on cleanrooms.

👉 Reserve your spot: https://www.cellgenetherapyreview.com/3980-Webinars/627505-From-bench-to-batch-Building-reproducible-cell-and-gene-therapy-workflows-with-GMP-ready-reagents/

09/01/2026

Fall is just around the corner and that means we’re exhibiting at the BioProcess International (BPI) conference in Boston, MA, from September 22-25. 🍂 🦞 ⚓

This year we’re in the Cell & Gene Therapy International track, booth 1033. Andrew Sabatier, Amy Ma, Dave Briner, and Joyce Chee will be onsite to greet you.

They are ready to discuss any challenges or issues related to biopreservation best practices, cell culture optimization, cell processing platforms, automated water-free thawing, closed-system consumables, and flexible fluid management systems.

📲 Download the ConnectMe app to personalize your schedule. Make sure to block off time to stop by the BioLife booth.

If you haven’t registered yet, please take advantage of a 10% discount when you register with VIP code SPONSOR10 through the event website.

➡️ Book here: https://informaconnect.com/cell-therapy-bioprocessing/purchase/select-package/

08/27/2026

How can you improve your cell culture workflow and reduce lot-to-lot variability?

By choosing starting materials like recombinant proteins that have higher reproducibility, tighter quality control, are animal origin-free, carrier-free, and regulatory-ready. ✅

In a new webinar with Cell & Gene Therapy Review, Liz Stewart Stewart of Qkine and Dave Briner of BioLife Solutions will guide you through what is essential when choosing a cytokine or growth factor type; and why closed-systems and closed packaging are important to consider to reduce contamination risks, decrease costs, and improve manufacturing consistency. 🔄

📅 Wednesday, September 23
⌚ 11:00am EDT

Don’t miss out: https://www.cellgenetherapyreview.com/3980-Webinars/627505-From-bench-to-batch-Building-reproducible-cell-and-gene-therapy-workflows-with-GMP-ready-reagents/

08/25/2026

As we wrapped up The Cell Summit ’26 forum in partnership with Cincinnati Children's Hospital, a few unplanned topics arose and took an interesting turn.

🎙️ Attendees and speakers both spoke about how cell & gene therapy and biopharma industries need to do a better job of education, perception, and communication with the public.

🧠 These topics are very important in today’s climate of misinformation and a greater distrust in public health. Getting non-scientific individuals and families to understand the importance of biology and biologics in their everyday lives and on a larger, big-picture scale is paramount.

🤝 When the public is empowered with key knowledge of advanced therapies, they could become our biggest advocates for the industry-wide goals of expanding access and coverage, and instilling a deeper understanding of the scientific benefits for developers, regulators, and patients.

BioProcess International summarized this impromptu discussion here:
https://www.bioprocessintl.com/event-report/attendees-talk-public-communication-gap-at-cell-summit-2026

08/24/2026

🚨 FINAL CALL🚨

Sign up for this CAR-T/TCR Workflow webinar with Cell & Gene happening on Tuesday, August 25 at 11am EDT!

Overview:
🔬 The webinar focuses on improving the robustness, consistency, and scalability of autologous CAR-T/TCR manufacturing when using cryopreserved leukopaks as starting material. CARR Biosystems and BioLife Solutions will present a systematic evaluation of an end-to-end workflow, examining key steps such as washing, buffer exchange, cryopreservation, thawing, and final formulation.

Key Takeaways:
🔑 Hear a practical framework for defining operating ranges, reducing process variability, and developing scalable, closed-system manufacturing workflows.

Register now:

Tuesday, August 25, 2026 at 11:00 AM Eastern Daylight Time. As autologous cell therapy programs scale, variability in starting material and process conditions can limit manufacturing consistency. In this webinar, CARR Biosystems and BioLife Solutions present findings from a systematic evaluation of....

08/21/2026

How can the cell and gene therapy industry better balance the high manufacturing costs of advanced therapy products, while also demonstrating clinically meaningful benefits, creating a profit, and meeting the needs of rare disease populations?

At our recent Cell Summit ’26 forum, Ralph Brandenberger, Head of CMC at Dark Horse Consulting Group Inc. suggested that early planning, aligning expectations, and creating a TPP (target product profile) can greatly increase the likelihood of clinical and commercial success, while also balancing the requirements listed above. ⚖️✔️

The two biggest categories that gets challenged by regulators are analytical methods and CMC (Chemistry, Manufacturing, Controls) issues. Brandenberger explores key questions that will better prepare therapy companies for regulatory reviews and ultimately successful commercialization. 🔑

🔎 Find out the key questions: https://www.bioprocessintl.com/business/cell-summit-2026-maximizing-cgt-success-in-an-increasingly-challenging-landscape

Article by BioProcess International.

Ralph Brandenberger of Dark Horse Consulting Group told delegates at the Cell Summit that insufficient planning causes delays for CGT developers.

08/19/2026

The Cell Summit ’26 forum we co-hosted with Children’s Hospital on July 28-29 was recently covered by BioProcess International.

News Editor Josh Abbott shared highlights from speaker Tracy Gramer, Associate Director at CTI Clinical Trial & Consulting. Gramer spoke about the evolution of scaling clinical trials for cell and gene therapies, which includes where we stand today - in the “Emerging Access Era” of where capabilities need to be moved, not patients, to increase access. ⤴️

This type of strategy starts with evaluating hospitals and deciding which can be made therapy-ready to meet country-specific regulatory requirements. 🔓

Gramer also shared a case study involving Cincinnati Children’s and a young boy, Sriansh Ojha, with a rare genetic disorder called AADC deficiency, who was treated successfully in a clinical trial with a gene therapy that went on to become the now FDA-approved therapy, KEBILIDI™. 🧬

👉 Read more on the Emerging Access Era: https://www.bioprocessintl.com/emerging-therapeutics-manufacturing/cell-summit-2026-heralding-an-era-of-improved-patient-access-for-cgts

🎥 Watch Sriansh’s story: https://youtu.be/cIyDAG-HoR4?si=77N-KUw28CuxFuVX

08/13/2026

The next ScaleReady and Emily Whitehead Foundation G-Rex Grant Tour Stop is in ONE week on August 20!

Don’t miss this event if you’re in the Los Angeles area. 🌇 🌊⭐

Stop by the BioLife table to meet and chat with Amy Ma and Rebecca Mercier about improving your cryopreservation process, storage containers, closed-systems, thawing optimization, and more.

Highlights:

🌴 Two business roundtables
🌴 Hearing from CAR-T therapy patient-advocate Laurie Adami
🌴 Progress in solid tumor research with CAR-T therapy
🌴 Advancements in ex vivo CGT research

Register soon:

Join the G-Rex Grant Tour in Los Angeles, CA. Sign up to foster local collaboration, shape the future of cell therapy, and catalyze progress.

08/12/2026

Are you attending Phacilitate'a Advanced Therapies Europe in Barcelona, September 7-9? 🎨☀️

Come by to see us at Stand 54. Andreas Giger, Jordi Marti Gascon, and Carlos Santalla Formoso of Bexen Bioservices will be onsite.

They are here to discuss and help you work through any issues - from scaling up after R&D, navigating clinical trials, or optimizing biopreservation protocols for commercialization. We’re ready to work together to streamline and strengthen your processes.

Let’s get together over tapas, escalivada, and fideua! 🥘🦐

➡️ Find out more: https://www.phacilitate.com/advanced-therapies-europe

08/11/2026

Can an end-to-end autologous CAR-T/TCR workflow deliver consistent performance when starting with cryopreserved leukopaks?

On August 25, in a new webinar with Cell & Gene and CARR Biosystems, Dr. Alireza Abazari and Robert Bilsky will present their latest findings from this study. 💡

🔎 Both will examine how key processing steps and operating parameters affect cell health, cell recovery, viability, consistency, and overall manufacturing reproducibility.

🔎 You will also discover practical approaches for developing reproducible, closed-system workflows that enhance manufacturing reliability, minimize risk, and support efficient scale-up from clinical to commercial production.

Register here: https://event.on24.com/wcc/r/5256157/7AB18447AC92F573A7F7B76F046CB5C7?mode=login